AMSTERDAM (Reuters) - Mylan (NASDAQ:MYL) NV shareholders re-elected the generic drugmaker's board at its annual meeting on Thursday, despite a shareholder campaign to vote down most of the directors in the wake of a scandal related to its high prices for emergency allergy treatment EpiPen.
Shareholders voted against a measure to approve the company's executive compensation. The shareholder campaign against Mylan's board picked up steam after Chairman Robert Coury's nearly $100 million pay package was disclosed earlier this year.
The company did not disclose the vote totals for the directors.